157 related articles for article (PubMed ID: 12435053)
21. Lentivirus vectors: difficulties and hopes before clinical trials.
Kafri T
Curr Opin Mol Ther; 2001 Aug; 3(4):316-26. PubMed ID: 11525555
[TBL] [Abstract][Full Text] [Related]
22. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation.
Neschadim A; McCart JA; Keating A; Medin JA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1407-16. PubMed ID: 18022569
[TBL] [Abstract][Full Text] [Related]
23. Gene therapy for hemoglobinopathies: are we there yet?
Puthenveetil G; Malik P
Curr Hematol Rep; 2004 Jul; 3(4):298-305. PubMed ID: 15217560
[TBL] [Abstract][Full Text] [Related]
24. Expression of human factor IX gene in murine plasma through lentiviral vector-infected haematopoietic stem cells.
Chen H; Yao H; Huang L; Shen Q; Jia W; Xue J
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1196-201. PubMed ID: 17184501
[TBL] [Abstract][Full Text] [Related]
25. The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in beta-thalassemia patients.
Persons DA
Ann N Y Acad Sci; 2010 Aug; 1202():69-74. PubMed ID: 20712775
[TBL] [Abstract][Full Text] [Related]
26. Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia.
Hanawa H; Hargrove PW; Kepes S; Srivastava DK; Nienhuis AW; Persons DA
Blood; 2004 Oct; 104(8):2281-90. PubMed ID: 15198957
[TBL] [Abstract][Full Text] [Related]
27. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters.
Pluta K; Luce MJ; Bao L; Agha-Mohammadi S; Reiser J
J Gene Med; 2005 Jun; 7(6):803-17. PubMed ID: 15655804
[TBL] [Abstract][Full Text] [Related]
28. Multiply attenuated, self-inactivating lentiviral vectors efficiently transduce human coronary artery cells in vitro and rat arteries in vivo.
Céfaï D; Simeoni E; Ludunge KM; Driscoll R; von Segesser LK; Kappenberger L; Vassalli G
J Mol Cell Cardiol; 2005 Feb; 38(2):333-44. PubMed ID: 15698840
[TBL] [Abstract][Full Text] [Related]
29. Progress toward safe and effective gene therapy for beta-thalassemia and sickle cell disease.
Lebensburger J; Persons DA
Curr Opin Drug Discov Devel; 2008 Mar; 11(2):225-32. PubMed ID: 18283610
[TBL] [Abstract][Full Text] [Related]
30. [Development of gene therapy for hematopoietic stem cell using viral vectors].
Dong WJ; Zu ZX; Liu DP; Liang CC
Yi Chuan Xue Bao; 2003 Apr; 30(4):382-8. PubMed ID: 12812066
[TBL] [Abstract][Full Text] [Related]
31. Restoration of the balanced alpha/beta-globin gene expression in beta654-thalassemia mice using combined RNAi and antisense RNA approach.
Xie SY; Ren ZR; Zhang JZ; Guo XB; Wang QX; Wang S; Lin D; Gong XL; Li W; Huang SZ; Zeng F; Zeng YT
Hum Mol Genet; 2007 Nov; 16(21):2616-25. PubMed ID: 17716993
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
Persons DA
Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
[TBL] [Abstract][Full Text] [Related]
33. Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells.
Siapati EK; Bigger BW; Miskin J; Chipchase D; Parsley KL; Mitrophanous K; Themis M; Thrasher AJ; Bonnet D
Mol Ther; 2005 Sep; 12(3):537-46. PubMed ID: 16099415
[TBL] [Abstract][Full Text] [Related]
34. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
[TBL] [Abstract][Full Text] [Related]
35. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
Tiede A; Eder M; von Depka M; Battmer K; Luther S; Kiem HP; Ganser A; Scherr M
Gene Ther; 2003 Oct; 10(22):1917-25. PubMed ID: 14502221
[TBL] [Abstract][Full Text] [Related]
36. Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells.
Dropulic B
Curr Hematol Rep; 2005 Jul; 4(4):300-4. PubMed ID: 16009045
[TBL] [Abstract][Full Text] [Related]
37. High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors.
Ma Y; Ramezani A; Lewis R; Hawley RG; Thomson JA
Stem Cells; 2003; 21(1):111-7. PubMed ID: 12529558
[TBL] [Abstract][Full Text] [Related]
38. Lentivirus vectors in β-thalassemia.
Payen E; Colomb C; Negre O; Beuzard Y; Hehir K; Leboulch P
Methods Enzymol; 2012; 507():109-24. PubMed ID: 22365771
[TBL] [Abstract][Full Text] [Related]
39. Development of ecdysone-regulated lentiviral vectors.
Galimi F; Saez E; Gall J; Hoong N; Cho G; Evans RM; Verma IM
Mol Ther; 2005 Jan; 11(1):142-8. PubMed ID: 15585415
[TBL] [Abstract][Full Text] [Related]
40. Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors.
Ralph GS; Binley K; Wong LF; Azzouz M; Mazarakis ND
Clin Sci (Lond); 2006 Jan; 110(1):37-46. PubMed ID: 16336203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
